Posted by Michael Wonder on 25 Feb 2022
Noninvasix receives FDA breakthrough device designation for non-invasive monitoring technology for sepsis
23 February 2022 - LIVOx is first monitoring device to non-invasively monitor sepsis by detecting a key indicator of septic shock.
Noninvasix announced today that its LIVOx Central Venous Oxygenation Monitor has received breakthrough device designation from the U.S. FDA for non-invasive, real-time, continuous or spot monitoring of central venous oxygen saturation in adults at risk of septic shock.
